热门资讯> 正文
诺华获得FDA批准Fabhalta用于IgAN患者
2024-08-08 04:57
- Novartis (NYSE:NVS) has received FDA accelerated approval for its drug Fabhalta to be used in the reduction of proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapid disease progression, according to the agency’s website.
- According to the product's expanded label, continued approval for the indication could be contingent on a confirmatory clinical trial.
- Fabhalta is already approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria, or PNH. The product was approved in December 2023.
Other approved drugs for IgAN include Travere Therapeutics’ (TVTX) Filspari and Calliditas Therapeutics’ (CALT) Tarpeyo.
More on Novartis
- Novartis: Another Beat, Another Raise
- Why Novartis Deserves Your Attention After Q2 2024 Results
- Novartis AG (NVS) Q2 2024 Earnings Call Transcript
- Novartis sues FDA for approving Entresto generic
- Novartis' Scemblix granted FDA Priority Review status for front-line CML
推荐文章
华盛早报 | 亚马逊加入OpenAI“朋友圈”，股价大涨4%创新高！分析师唱多英伟达市值上8.5万亿美元
美股机会日报 | 大摩警告！若薪酬方案被否，特斯拉或跌超10％；微软获批向阿联酋出口最新款英伟达芯片
美债上演大反攻 “Sell America”大错特错! 嘴上喊“美国例外论坍塌”的机构实际上狂买美债?
华盛早报 | 美政府“停摆”逼近历史记录！巴菲特卸任前最后财报：伯克希尔3817亿美元现金储备创新高，营业利润激增34%；美股今起进入冬令时
明略科技-W今日上市：香港公开发售获4452.86倍认购
新能源汽车“银十”热销 多家车企交付量破纪录
英伟达市值突破 5 万亿：回顾它与加密货币的曾经蜜月期
“股神”巴菲特旗下伯克希尔财报出炉，现金储备超3800亿美元创历史记录！速看前五大持仓
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
